PURPOSE: Low-molecular-weight cyclin E (LMW-E) in breast cancer cells induces genomic instability and resistance to inhibition by p21, p27, and fulvestrant therapy. Here, we sought to determine if LMW-E renders breast cancer cells unresponsive to aromatase inhibitors (AI), elucidate the mechanism of such resistance, and ascertain if inhibitors of LMW-E-associated kinase activity could overcome this resistance. EXPERIMENTAL DESIGN: The antiproliferative effects of the AIs were examined in aromatase-overexpressing MCF-7/Ac1 cells in the presence or absence of full-length cyclin E and LMW-E. Inhibition of LMW cyclin E kinase activity by roscovitine [a cyclin-dependent kinase (CDK) inhibitor] was examined in letrozole-unresponsive MCF-7/Ac1 cells. The role of LMW-E and CDK2 in mediating recurrence following AI treatment was also assessed in breast cancer patients. RESULTS: Overexpression of LMW-E in postmenopausal patients was associated with a poor prognosis. Letrozole, but not exemestane or anastrozole, mediated a pronounced G(1) arrest in MCF-7/Ac1 cells. Androstenedione-induced G(1) exit correlated with increased cyclin E-associated kinase activity and increased CDK2 levels. Letrozole treatment inhibited cyclin E-CDK2 kinase activity by preventing the androstenedione-induced increase in CDK2. LMW-E bypassed this effect and rendered the cells resistant to letrozole inhibition. Roscovitine blocked the androstenedione-induced increase in CDK2, and LMW-E overexpression could not bypass this effect. Lastly, breast cancer patients whose tumors overexpress LMW-E were not responsive to AI treatment. CONCLUSIONS: Roscovitine treatment can reverse intrinsic or acquired resistance to letrozole due to LMW-E expression in breast cancer cells. These data support the clinical investigation of CDK2 inhibitor therapy for postmenopausal women with estrogen receptor-positive, LMW-E-expressing breast cancer.
PURPOSE: Low-molecular-weight cyclin E (LMW-E) in breast cancer cells induces genomic instability and resistance to inhibition by p21, p27, and fulvestrant therapy. Here, we sought to determine if LMW-E renders breast cancer cells unresponsive to aromatase inhibitors (AI), elucidate the mechanism of such resistance, and ascertain if inhibitors of LMW-E-associated kinase activity could overcome this resistance. EXPERIMENTAL DESIGN: The antiproliferative effects of the AIs were examined in aromatase-overexpressing MCF-7/Ac1 cells in the presence or absence of full-length cyclin E and LMW-E. Inhibition of LMWcyclin E kinase activity by roscovitine [a cyclin-dependent kinase (CDK) inhibitor] was examined in letrozole-unresponsive MCF-7/Ac1 cells. The role of LMW-E and CDK2 in mediating recurrence following AI treatment was also assessed in breast cancerpatients. RESULTS: Overexpression of LMW-E in postmenopausal patients was associated with a poor prognosis. Letrozole, but not exemestane or anastrozole, mediated a pronounced G(1) arrest in MCF-7/Ac1 cells. Androstenedione-induced G(1) exit correlated with increased cyclin E-associated kinase activity and increased CDK2 levels. Letrozole treatment inhibited cyclin E-CDK2 kinase activity by preventing the androstenedione-induced increase in CDK2. LMW-E bypassed this effect and rendered the cells resistant to letrozole inhibition. Roscovitine blocked the androstenedione-induced increase in CDK2, and LMW-E overexpression could not bypass this effect. Lastly, breast cancerpatients whose tumors overexpress LMW-E were not responsive to AI treatment. CONCLUSIONS:Roscovitine treatment can reverse intrinsic or acquired resistance to letrozole due to LMW-E expression in breast cancer cells. These data support the clinical investigation of CDK2 inhibitor therapy for postmenopausal women with estrogen receptor-positive, LMW-E-expressing breast cancer.
Authors: Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus Journal: N Engl J Med Date: 2002-11-14 Impact factor: 91.245
Authors: Giuseppe Viale; Anita Giobbie-Hurder; Meredith M Regan; Alan S Coates; Mauro G Mastropasqua; Patrizia Dell'Orto; Eugenio Maiorano; Gaëtan MacGrogan; Stephen G Braye; Christian Ohlschlegel; Patrick Neven; Zsolt Orosz; Wojciech P Olszewski; Fiona Knox; Beat Thürlimann; Karen N Price; Monica Castiglione-Gertsch; Richard D Gelber; Barry A Gusterson; Aron Goldhirsch Journal: J Clin Oncol Date: 2008-11-03 Impact factor: 44.544
Authors: Daniele Generali; Francesca M Buffa; Alfredo Berruti; Maria P Brizzi; Leticia Campo; Simone Bonardi; Alessandra Bersiga; Giovanni Allevi; Manuela Milani; Sergio Aguggini; Mauro Papotti; Luigi Dogliotti; Alberto Bottini; Adrian L Harris; Stephen B Fox Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Ramon Colomer; Mariano Monzo; Ignasi Tusquets; Juli Rifa; José M Baena; Agusti Barnadas; Lourdes Calvo; Francisco Carabantes; Carmen Crespo; Montserrat Muñoz; Antonio Llombart; Arrate Plazaola; Rosa Artells; Monstsrrat Gilabert; Belen Lloveras; Emilio Alba Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531
Authors: Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi Journal: Am J Pathol Date: 2016-05-13 Impact factor: 4.307
Authors: Elena Shagisultanova; Lyndsey S Crump; Michelle Borakove; Jessica K Hall; Aryana R Rasti; Benjamin A Harrison; Peter Kabos; Traci R Lyons; Virginia F Borges Journal: Mol Cancer Ther Date: 2021-11-02 Impact factor: 6.261